Clinical Trial Update: MK0767 and Sulfonylurea Combination Study (0767-027) [Phase 3]

View source ↗

Summary

A Phase 3 study (0767-027) evaluating MK-0767 in combination with a sulfonylurea for type 2 diabetes was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MK-0767
• Sulfonylurea (unspecified)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: TERMINATED